Document is current
Any future updates will be listed below
-
Authors
Hsu, Lillian
Siegel, Julie
Nasarre, Patrick
Oberholtzer, Nathaniel
Mukherjee, Rupak
Hilliard, Eleanor
Chakraborty, Paramita
Burge, Rachel A.
O’Quinn, Elizabeth C.
Sweatt, Olivia
Kassir, Mohamed Faisal
Hobbs, G. Aaron
Ostrowski, Michael
Broome, Ann-Marie
Mehrotra, Shikhar
Klauber-DeMore, Nancy
-
Funding
Funding for this research was provided by:
Hollings Cancer Center Abney Fellowship
National Cancer Institute (P30 CA138313, P30 CA138313, P30 CA138313, P30 CA138313)
Congressionally Directed Medical Research Programs (W81XWH-18-1-0007, W81XWH-18-1-0007)
South Carolina SmartState™ Program
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 11 November 2025
First Online: 5 December 2025
Declarations
:
: IRB exemption was obtained to use four de-identified FFPE human TNBCs from the MUSC Biorepository and Tissue Analyses Shared Resource. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at MUSC and conducted in accordance with the National Institutes of Health guide for the care and use of laboratory animals.
: Not applicable.
: A Humanized Monoclonal Antibody to SFRP2 for Tumor-Associated Macrophage Reduction and Polarization in Cancer, Patent application # 63/568,165, Nancy Klauber-DeMore, Lillian Hsu, Patrick Nasarre, March 21, 2024. Discovery of Novel Targets for Angiogenesis Inhibition, Patent application # 61/053397, Inventor: Nancy Klauber-DeMore, MD. Pharmaceutical Combination for the Treatment of Cancer, Provisional patent # 112746-99263, Inventor: Nancy Klauber-DeMore, MD. Compositions and Methods Comprising SFRP2 Antagonists, Patent application # PCT/US2021/062854, Inventor: Nancy Klauber-DeMore, MD. Dr. Nancy Klauber-DeMore is a co-founder of Enci Therapeutics, Inc. and co-founder of Innova Therapeutics, Inc. The remaining authors declare no disclosures.
